



British Uro-oncology Group (BUG)

Annual Meeting Birmingham Metropole 12-13 September 2025

PROGRAMME

FRIDAY 12 September

10.00	Registration, refreshments, exhibition and poster viewing
11.00-12.30	Welcome <i>Amit Bahl, Chair, BUG</i> Uro-oncology round up - Prostate systemic therapy <i>Anuradha Jayaram, Consultant Medical Oncologist & Honorary Clinical Lecturer, University College London Hospital NHS Foundation Trust & UCL Cancer Institute</i> - Prostate radiation therapy <i>Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast</i> - Bladder <i>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</i> - Renal <i>Lisa Pickering, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust</i> - Testicular <i>Robert Huddart, Professor and Honorary Consultant in Urological Oncology, Institute of Cancer Research</i> - Penile EPIC <i>Amit Bahl, Consultant Clinical Oncologist, University Hospitals Bristol</i>
12.30	Lunch, exhibition and poster viewing
13.30-14.30	Seminar sessions 1
1A	Where do you stand on ARPI plus PARPI? Chair: <i>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</i> <i>Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre</i> <i>Anna Wilkins, Consultant Clinical Oncologist, Institute of Cancer Research</i>
1B	Survivorship in Uro-oncology Chair: <i>Robert Huddart, Professor and Honorary Consultant in Urological Oncology, Institute of Cancer Research</i> - Diet and dietary modification in care of prostate cancer <i>Robert Thomas, Consultant Oncologist, Addenbrooke's, Bedford, UCLH</i> - Integrating exercise interventions into the NHS cancer clinical pathway <i>Derek J Rosario, Consultant Urological Surgeon and Honorary Professor, Sheffield Hallam University</i> - The value of Holistic care in testicular and prostate survivors speaker <i>tba</i>
1C	Update in mRCC management: a case based discussion Chair: <i>Amarnath Challapalli, Consultant Clinical Oncologist, Bristol Cancer Institute</i> - The role of SABR in primary RCC <i>Anjali Zarkar, Consultant Clinical Oncologist, University Hospitals Birmingham</i> - Belzutifan in VHL cases <i>Balaji Venugopal, Consultant in Medical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow</i>



British Uro-oncology Group (BUG)

Annual Meeting Birmingham Metropole 12-13 September 2025

	Post adjuvant Pembro failures and Tx choices <i>Amarnath Challapalli, Consultant Clinical Oncologist, Bristol Cancer Institute</i>
14.30-15.30	The future of AI Chair: <i>Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre</i> - How AI works: an introduction for the uninitiated <i>Robert Insall, Professor of Computational Cell Biology, University College London</i> - The role of AI in Radiotherapy <i>Alan McWilliam, Reader, University of Manchester</i> - AI in Uro-pathology <i>Clare Verrill, Professor of Cellular Pathology and Artificial Intelligence, University of Oxford</i>
15.30	Refreshments, exhibition and poster viewing
16.00	Urothelial cancer rapid fire debates with voting Chair: <i>Simon Hughes, Consultant Clinical Oncologist, Guy's & St Thomas' NHS Foundation Trust</i> - The patient's perspective <i>Melanie Costin, Director of Patient Engagement & Support, Fight Bladder Cancer</i> 1. Upper tract disease: systemic treatment, when's the right time - Neoadjuvant <i>Jim Catto, Professor of Urology, University of Sheffield</i> - Adjuvant <i>Alison Birtle, Consultant Oncologist, Rosemere Cancer Centre, Lancashire Teaching Hospitals</i> 2. NMIBC – my option is better than yours - Intravesical/surgery <i>Jonathan Aning, Consultant Urological Surgeon, North Bristol NHS Trust</i> - RT <i>Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust & University of Manchester</i> - Systemic <i>Dominique Parslow, Consultant Clinical Oncologist, University Hospitals Plymouth NHS Trust</i> 3. Node positive Muscle invasive bladder cancer with good response to chemotherapy- what's the next step - Systemic + surgery <i>Krishna Narahari, Consultant Urological Surgeon and Professor of Urology, University Hospital of Wales & Cardiff University</i> - Systemic + RT <i>Martin Swinton, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</i> - Systemic alone <i>Hilary Glen, Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow</i>
17.00	Why should you look at my poster? Chair: <i>Mark Beresford, Consultant Clinical Oncologist, Royal United Hospital, Bath</i> One minute presentations from each poster author
17.30-18.15	Welcome reception, exhibition and poster viewing
19.30	Predinner drinks
20.00	Conference dinner



British Uro-oncology Group (BUG)

Annual Meeting Birmingham Metropole 12-13 September 2025

SATURDAY 13 September

08.15	Registration, refreshments, exhibition and poster viewing
08.45-09.15	BUG Annual General Meeting Review of 2024/2025 activity Members only
09.15-10.15	National audits update Chair: <i>Amit Bahl, Chair, BUG</i>
09.15	NPCA <i>Alison Tree, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust</i>
09.30	NKCA <i>Raghav Varma, ST6 Urology Trainee, The London School of Hygiene & Tropical Medicine & Royal College of Surgeons</i>
09.45	Bladder: RCR MIBIC Reaudit <i>Mohini Varughese, Consultant Clinical Oncologist, Royal Devon University Hospitals NHS Foundation Trust</i> Discussion
10.10	NHS England and British Uro-oncology Group Survey: National Insights into Radiotherapy pathway timings for Intermediate and High-Risk Prostate Cancer <i>Zainul Abedin Kapacee, Clinical Oncology Registrar, The Christie NHS Foundation Trust</i>
10.15	Helen Patterson Award for Registrar Research Chair: <i>Robert Huddart, Professor and Honorary Consultant in Urological Oncology, Institute of Cancer Research</i>
10.15	Chair's welcome
10.20	2024 Winner's presentation <i>Nicola Hill, Consultant Clinical Oncologist, Belfast Health & Social Care Trust</i>
10.25	Oral presentations
10.30	1. Decreased skeletal muscle quantity is associated with inferior overall survival in bladder cancer patients treated with radiotherapy <i>Alexander Vickers, Clinical Oncology SpR & Honorary Research Fellow, The Christie NHS Foundation Trust</i>
10.40	2. Treatment patterns and outcomes in men aged 50+ with Germ Cell Tumours <i>Marija Miletic, Clinical Fellow in Uro-oncology, The Royal Marsden NHS Foundation Trust</i>
10.50	3. Target delineation for prostate radiotherapy (prostate and boost volume): Evaluating differences in an RTQA contouring exercise for the PIVOTALboost trial <i>Jasima Latif, Clinical Oncology Registrar, Clatterbridge Cancer Centre NHS Trust</i>
11.00-11.30	Refreshments, exhibition and poster viewing



British Uro-oncology Group (BUG)

Annual Meeting Birmingham Metropole 12-13 September 2025

11.30-12.45	Seminar sessions 2
2A	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues <i>Chairs: Alison Birtle, Consultant Oncologist, Rosemere Cancer Centre, Lancashire Teaching Hospitals and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust & University of Manchester</i> Panel: • <i>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</i> • <i>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</i> • <i>Niyati Lobo, Consultant Urological Surgeon, Cambridge University Hospitals NHS Foundation Trust</i> • <i>Phillipe Taniere, Consultant Histopathologist/Molecular Pathology, Birmingham</i> • <i>Rashid Amir, Consultant Abdominal Radiologist, Queen Elizabeth Hospital Birmingham</i>
2B	Imaging in prostate cancer management <i>Chair: Suneil Jain, Consultant Clinical Oncologist, Queen's University, Belfast</i> • <i>Staging, BCR, oligometastases Tara Barwick, Consultant Radiologist and Professor of Practice (Cancer Imaging), Imperial College Healthcare NHS Trust</i> • <i>Response assessment and theranostics Sairah Khan, Consultant Nuclear Medicine Physician and Radiologist, Imperial College Healthcare NHS Trust</i> • <i>Whole body MRI Anwar Padhani, Consultant Radiologist and Professor of Cancer Imaging, Paul Strickland Scanner Centre</i>
2C	When things go wrong.... <i>Chair: Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre</i> Case based legal discussions/Coroner's inquest/Legal aspects • <i>Jeremy Roussak, Barrister, Kings Chambers, Manchester</i> • <i>Peter Hoskin, Consultant Clinical Oncologist, Mount Vernon Hospital</i>
12.45	Closing session <i>Chair Amit Bahl, Chair BUG</i> Prize giving Helen Patterson Award for registrar research Best poster prize
13.00-14.15	Lunch and depart



British Uro-oncology Group (BUG)

Annual Meeting Birmingham Metropole 12-13 September 2025

BUG would like to thank the following organisations for their support of the
2025 Annual Meeting

KEY SPONSORS



SUPPORTING SPONSORS



BUG recognise the ABPI Code of Practice and the implications for pharmaceutical companies that support the Annual meeting by way of sponsoring and exhibiting.
Industry partners have no input into the educational content of the programme